Delayed Graft Function by Li, Qiansheng et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors




the world’s leading publisher of
Open Access books






Delayed Graft Function 
Qiansheng Li, Wenqian Huo, Keqin Zhang, Gang Wu,  
Fengshuo Jin, Xi Lin, Xiaojiang Jiang and Dong Gao 
Department of Urology, Institute of Surgery Research, Daping Hospital,  
Third Military Medical University, Chongqing, 
China 
1. Introduction 
Delayed graft function (DGF) is a common complication of renal transplantation. According 
to a clinical data analysis of 34,647 cases of cadaveric renal transplantation documented by 
the Renal Transplantation Registry of the United Network Sharing (UNOS), graft function 
did not recover instantly after transplantation and for ever in some cases; the 1-year rate of 
graft loss was up to 20% in cases with poor renal function recovery; the long-term loss rate 
of graft was higher in cases with poor renal function recovery than those with instant graft 
function. The half-life time of graft is 7 years in cases with delayed graft function, and is 12 
years in cases with instant graft function. Based on our 30 years of experience in renal 
transplantation and the literature, we reviewed the diagnosis and management of DGF.  
2. Diagnostic criteria 
Currently, graft function recovery is defined as follows.  
1. Instant graft function (IGF): postoperative urine output >7000ml, serum creatinine 
recovery to normal in 3-7 days.  
2. Slow graft function (SGF): postoperative urine output is normal, but serum creatinine 
decreases slowly, and not to normal in one week. Nevertheless, dialysis is not needed.  
3. Delayed graft function (DGF): DGF can be diagnosed according to the three aspects 
below.  
i. Need for postoperative dialysis: Need for dialysis in the first week after transplant 
once hyperacute rejection, vascular and urinary tract complications and 
hyperkalemia are ruled out.  
ii. Urine output and serum creatinine: p Rise in serum Cr at 6–8 h post-operatively 
or <300 ml of urine despite adequate volume and diuretics. q Urine output <1 L in 
24 h and <25% fall in serum creatinine from baseline in first 24 h post-transplant. r 
Urine output <75 mL/h in first 48 h or failure of serum Cr to decrease by 10% in 
the first 48 h. s Serum creatinine increases or remains unchanged or decreases 
<10%/day during 3 consecutive days postoperatively. t Serum creatinine >2.5 
mg/dL on Day 7 or need for post-transplant hemodialysis. u Time required for the 
kidney to reach CrCl>10 mL/min greater than 1 week. v Failure of creatinine to 
decline in the first 48 h in the absence of rejection.  
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iii. Urine enzymes and biopsy: p Urine IL-18 in first 24 h>500 pg/mg. qUrine 
NGAL on Day 0 >1000 ng/mg and IL-18 on Day 0 > 500 pg/mg. rPre-transplant 
soluble IL-6R of 35 000 pg/mL. s Pathologic findings that support acute renal 
tubular necrosis.  
4. No more graft function (NGF): Postoperative failure of graft function that requires 
dialysis.  
5. Hyper delayed graft function (HDGF): In rare cases, the anuria stage persists longer 
than one month, even several months after renal transplantation, followed by gradual 
renal function recovery, a phenomenon we called HDGF. In 2000, we performed a 
second renal transplantation in a female patient. In this patient, the anuria stage lasted 
109 days postoperatively, and urine output increased gradually, with serum creatinine 
decrease to normal on day 155 postoperatively. Ten years of follow-up indicated the 
graft function to be normal.  
3. Risk factors for DGF 
DGF is a complex pathologic process usually involved donor- and recipient-related factors. 
Donor-related factors include age, cause of death, and transplantation and cold ischemia 
time of graft. Recipient-related factors include rejection, anti-HLA antibody level, and times 
of renal transplantation, cytomegalovirus infection, obesity, body size difference with the 
donor, pre-transplant dialysis type, and ethnicity.  
1. Donor-related factors Due to an organ shortage, organs from donors of advanced age or 
organs with other confounding diseases are also used as sources for organ 
transplantation. The quality of renal graft is crucial. Renal graft function is closely 
associated with the donor’s age, cause of death and primary disease. Renal graft of poor 
quality may not survive for long because of immune or non-immune damage to the 
graft.  
i. Brain death Animal study has demonstrated that changes in physiology, 
hemodynamics, endocrinology, and histomorphology as well as early 
inflammation damage peripheral organs following brain death. Cytokine storm 
after brain death may upregulate HLA expression in the graft and make the graft 
susceptible to attack by preexisting anti-HLA antibody. Rejection occurred earlier 
in renal grafts from rats after brain death than in the control group. The survival 
rate of renal grafts from non-kinship living donors is much higher than that of 
cadaveric renal grafts. Brain death influences the quality of donor organ, increasing 
the incidence of DGF.  
ii. Senile donors It has been clinically shown that senility of donors is a major risk 
factor for DGF, and it influences the long-term survival of grafts. The UN data 
demonstrate that senility of donor increases the incidence of DGF significantly. For 
instance, the incidence of DGF is 15% if the donors’ age is 20 years, and is up to 
40% if the donor’s age is over 65 years. The cause for such difference may lie in the 
fact that the number of functioning nephrons decreases in healthy individuals with 
aging. In addition, renal grafts may be injured by ultrafiltration following 
transplantation.  
iii. Cause of death The cause of death is another major risk factor influencing the long-
term survival of graft. According to the UNOS data, the incidence of DGF was 18% 
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if the donors died of traffic accident, was 30% if the donors died of cerebrovascular 
accident, and was 45% in 400 non-heart-beating donors (NHBDs) (possibly related 
to long periods of warm ischemia).  
iv.  Ischemia-reperfusion injury Cessation of blood flow leads to anaerobic metabolism 
and adenosine triphosphate depletion in the organ. The incidence of DGF is 12% if 
the period of cold ischemia of renal graft is less than 12h, and is up to 45% if the 
period of cold ischemia exceeds 48h. In addition, the incidence of DGF is less than 
10% if the donor is young and the cold ischemia time is less than 12h, and is more 
than 20% if the donor is senile and the cold ischemia time is short. Given the cold 
ischemia time of 36-48h, the incidence of DGF is up to 50% if the donor is senile 
and, and is only 30% if the donor is young. Animal study has shown that the 
donor’s age and cold ischemia time exert additive effect on chronic graft rejection.  
2. Recipient-related factors  
The incidence of DGF is relatively high given suboptimal HLA matching, high 
sensitization status and a second transplantation. The severity of immune injury 
depends mainly on the severity of early post-transplantation rejection. High 
sensitization status increases the risk of immune injury. DGF may mask rejection, but 
rejection may aggravate preexisting injury. It has been demonstrated that the incidence 
of DGF increases significantly in the presence of early graft rejection and DGF is a 
predictor for aggravation of rejection. Cytomegalovirus infection, obesity, type of pre-
transplant dialysis, and ethnicity are all factors influencing the incidence of DGF. For 
instance, black recipients are more likely to develop DGF than other people. However, 
the mechanisms involved remain largely unknown.  
3. Other factors  
i. Organ preservation: Continuous pulsatile perfusion or pulsatile perfusion plus 
simple cold preservation of grafts from NHBDs helps decrease the incidence of 
DGF and improve the long-term survival rate of graft. In NHBDs, comparison of 
bilateral kidneys subjected to pulsatile perfusion and simple cold preservation, 
respectively, showed that the incidence of DGF was 10% for grafts subjected to 
pulsatile perfusion, and was 30% for grafts subjected to simple cold preservation. 
Valero, et al analyzed in situ perfusion (ISP), total body cooling (TBC), and 
normothermic recirculation (NR) for grafts from NHBDs, and found that the 
incidence of DGF was significantly lower in grafts subjected to NR than in those 
subjected to ISP and TBC. The viability of grafts from NHBDs can be assessed by 
perfusion parameters, and be improved through infusing drugs. In 2009, Cyril 
Moers reported that Lifeport Transporter can significantly decrease the incidence 
and duration of DGF following renal transplantation, while significantly increasing 
the 1-years survival rate of graft. In addition, Lifeport Transporter provides useful 
information for professionals to make wise clinical decisions, and helps them 
choose renal grafts. Hence, Lifeport Transporter is an effective, economical device 
for renal graft preservation.  
Shortening the ischemia time: Topical ischemia/reperfusion injury is the pathogenetic basis 
for DGF, and the severity of DGF depends on the duration of ischemia. The incidence of 
DGF is lower in China than in other countries. This is because the warm ischemia time 
(WIT) of cadaveric renal graft is usually maintained between 10 and 15min in the 
transplantation centers in China. The warm ischemia time should also be shortened during 
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nephrectomy in living donors. It helps reduce the incidence of DGF to shorten the time for 
graft trimming and possible second warm ischemia of graft. The cold ischemia time (CIT) 
directly influences the incidence of DGF and graft survival. It was demonstrated that the 
risk of DGF increased by 23% every 6h.  
Kidney preservatives: They are used to minimize topical ischemic injury. They comprise 
special components to relieve cellular swelling, maintain calcium homeostasis, reduce the 
production of oxyradicals and provide energy-rich substances. The UW preservative is 
superior to Euro-Collins solution in reducing the incidence of DGF. The research on 
preservatives is now focusing on additives to the standard formulas, e.g., Trimetazidine.  
ii. Recipient management: Many patients have inadequate blood volume 
preoperatively, and the use of crystalline or colloid solutions under central venous 
pressure monitoring can reduce the incidence of DGF. The kidney is one of the 
organs that need plentiful blood supply, and the volume of blood supplied to the 
kidneys accounts for approximately 1/4 of cardiac output. The kidney is sensitive 
to ischemia, and the ischemia time is correlated to the severity of reperfusion-
related injury. Appropriate blood pressure is a prerequisite for adequate graft 
perfusion. In particular, the blood pressure in the recipient prior to reperfusion 
determines the recovery of metabolism of graft after a series of ischemic events. A 
proper blood pressure ensures oxygenated blood perfusion and benefits graft 
functional recovery. The incidence of DGF is lower in patients receiving peritoneal 
dialysis prior to transplantation than those receiving hemodialysis. This may relate 
to decreased blood volume in patients receiving hemodialysis upon the procedure 
of transplantation. Therefore, sufficient fluid extension is beneficial for patients. 
Effective blood pressure must be maintained intra- and post-operatively, and blood 
pressure should better be kept 10-20mmHg (1mmHg=0.133kPa) above the basic 
blood pressure upon reperfusion and in the first three days postoperatively, thus 
ensuring effective graft perfusion. Stable blood pressure but poor graft vessel 
tension and anuria during operation may relate to arteriospasm that results from 
traction of the renal artery. Polyuria may be induce by postoperative 
administration of dopamine to dilate the renal artery and elevate systolic pressure.  
iii. Vasodilators: During reperfusion, direct infusion of calcium channel blockers into 
the renal artery improves early renal function due to direct vasodilation and relief 
of lipid peroxide. A randomized trial has demonstrated that dilthiazem treatment 
of the donor or treatment of the recipient with other calcium channel blockers 
benefits early graft function. Atrial natriuretic peptide (ANP), a peptide hormone 
increasing glomerular filtration rate and urine output, improves renal function and 
histopathologic changes in animals with acute ischemic renal failure. After infusion 
of ANP increases serum creatinine clearance quickly and reduces the need for 
dialysis. In addition, ANP antagonizes vasoconstrictors following topical ischemic 
injury and promotes renal function recovery. Furosemide suppresses prostaglandin 
lyases and increases prostaglandin E, thus dilating renal vessels, decreasing renal 
vascular resistance, and increasing blood flow to the kidney, particularly to the 
tissues under renal cortex. Therefore, furosemide can relieve ischemic renal injury, 
promote renal function recovery, and decrease the incidence of DGF.  
iv. HLA mismatching: Based on our data, HLA is no a risk factor for DGF, possibly 
because we controlled the number of HLA mismatches strictly. In addition, HLA 
matching directly influences the incidence of AR, and AR is one risk factor for 
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DGF. We also found that early urinary fistula and ureteral obstruction are not risk 
factors for DGF. 
v. Type of dialysis: The type of pre-transplant dialysis may influence the incidence of 
DGF. A review of a number of cases showed that peritoneal dialysis is in favor of 
immediate recovery of renal function after renal transplantation, which was 
attributed to fluid load in the recipient. After analysis of multiple variables, e.g., 
DGF, ARF in patients who underwent preoperative hemodialysis (HD) or 
peritoneal dialysis (PD) and received the first cadaveric renal transplantation, it 
was found that there were 33 cases of DGF (27 cases of HD and 6 cases of PD, 
p=0.03, and there were 14 cases of ARF (14 cases of HD and 0 case of PD, p=0.01). 
The time for serum creatinine to decrease to 50% of the pre-transplant level 
correlates positively to the cold ischemia time and body weight increase in the 
recipient, and correlates negatively to the urine output in the first 24h, fluid load, 
and central venous pressure. PD is thought to decrease the incidence and severity 
of DGF after renal transplantation. Joseph, et al investigated acute rejection, DGF, 
graft survival, and patient survival in 325 patients who underwent preoperative 
HD and PD and the first cadaveric renal transplantation, and found 56 DGF cases 
in 183 PD patients and 58 DGF cases in 117 HD patients. The incidence of DGF was 
significantly higher in HD patients than in PD patients.  
4. Mental disorders and interventions in DGF patients  
With technical advance in renal transplantation, mental problems in patients with renal 
failure or undergoing renal transplantation have drawn more and more attention. These 
problems include personality change, emotional disorders, mental disorders, 
psychological rejection, and psychosocial dysfunction. Mental problems may directly 
influence graft function recovery, and even lead to graft nonfunction or serious adverse 
events, such as non-compliance to treatment or automutilation (suicide). Therefore, it is 
crucial to pay close attention to the patient’s mental status before and after renal 
transplantation and manage mental disorders promptly.  
Because of biological factors, e.g., renal failure and rejection, immunosuppressant-associated 
adverse reactions and psychosocial factors, patients may develop various mental disorders 
before and after renal transplantation, including anxiety, depression, psychotic symptoms, 
and psychological rejection. Anxiety/depression disorder is characterized by mental stress, 
excessive anxiety, worry, depression, self-abasement, self-blame, and decreased interest. 
Some patients may present with panic attack and social anxiety disorder, and serious 
patients may have suicidal idea and commit suicide. Psychotic symptoms include delusion, 
hallucination, lack of self-awareness due to mental and somatic disorders, and detachment 
of the real world. Patients with psychotic symptoms may suffer from secondary behavioral 
disorders. These symptoms persist for varying length of time. Psychological rejection occurs 
mainly after renal transplantation. The patients are unable to accept the grafts mentally, and 
they cannot cope with the mental stress associated with transplantation. They may refuse to 
take anti-rejection drugs or ask for removal of the grafts. These mental disorders may cause 
autonomic nerve dysfunction, immune dysfunction and behavioral disorders, e.g., somatic 
pain, insomnia, anorexia (or apastia), and non-compliance to treatment or automutilation 
(suicide).  
Most patients expect much from renal transplantation, and they are likely to develop mental 
disorders in case of DGF. There are interacting biological and psychosocial factors that 
underlie mental disorders.  
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1. Biological factors:  
i. Acute renal failure  
Following renal transplantation, ATN leads to accumulation of toxic substances 
which damage nerve cells directly or indirectly and influence nerve cell functions. 
For instance, alteration in intracerebral monamine neurotransmitters may lead to 
anxiety, depression and psychotic symptoms.  
ii. Immunosuppressants  
Large doses of immunosuppressants may impair the immune system, and interfere 
with neuroendocrine function and neurotransmitters in the brain. Neuroendocrine 
and neurotransmitter dysfunction serve the principal biological mechanism for 
mental disorders in DGF patients.  
iii. Transplantation procedure 
Renal transplantation procedure per se is a traumatic stress, which can also cause 
mental disorders, particularly in patients with poor physical status. In addition, 
perioperative administration of medications, e.g., anesthetics, is one of the causes 
for mental disorders in DGF patients.  
2. Psychosocial factors:  
i. Personality  
Positive and optimistic attitude, good cognition assessment system and coping 
capacity are crucial for mental health of patients undergoing renal transplantation. 
Personality traits such as anxiety, paranoid idea, and disadvantage-guided thought 
are the personality basis for mental disorders in DGF patients.  
ii. Stressful events  
In case of accumulation of adverse life events or major adverse life events, DGF 
patients may suffer from serious mental trauma and mental disorders.  
iii. Psychosocial supportive system  
The psychosocial supportive system for DGF patients involves social security 
system, family support and other interpersonal support. Social security system 
includes medical insurance and psychological support (e.g., unemployment). 
Family support mainly involves husband-wife and parent-child relationships and 
socioeconomic status of family. Other interpersonal support mainly includes 
career, friendship and special group relationships.  
Proper assessment and effective management of DGF patients with mental disorders 
directly influence the efficacy of medical interventions and the life quality of patients.  
3. Assessment of mental disorders:  
i. The patient is interviewed face-to-face by psychiatrist and psychologist to assess 
his/her mental status, personality traits and life events. Meanwhile, the need for 
medical management and the specific interventions, e.g., psychological 
intervention or medical treatment, are evaluated.  
ii. Mental status scale based measurements: including measurements of mental status, 
personality traits, life events and life quality.  
4. Prevention of mental disorders:  
i. To establish an integrated social security supportive system, including medical 
insurance system and government funded special social security system.  
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ii. To set up a team of psychiatrists or psychologists, who monitor the patients’ mental 
status during the perioperative stage of renal transplantation, and diagnose and 
treat mental problems promptly.  
iii. To educate DGF patients, including introducing renal transplantation related issues 
and possible mental problems.  
5. Treatment of mental disorders:  
i. Psychotherapy  
Individualized psychotherapy, primarily supportive psychotherapy, is considered. 
Cognitive and behavioral therapy may also be utilized. In addition, volunteers who 
ever suffered from DGF and now have their renal function recovered normal are 
invited to communicate with the patients, which is the most effective modality.  
ii. Drug treatment  
In DGF patients with serious mental disorders, antipsychotic drugs, e.g., 
Olanzapine, may be prescribed. The dose must be increased gradually. In case of 
serious emotional disorder, e.g., anxiety-depression, particularly, high risk of 
suicide, antidepressant drugs should be administered immediately. SSRI and SSNI 
drugs may be prescribed. For patients with serious anxiety, benzodiazepines may 
be used. Electroshock should be considered with caution.  
4. Prevention and management of DGF 
DGF leads to adverse outcomes, including prolonged hospital stay, need for postoperative 
hemodialysis, significant increase in medical care costs, decrease in the 1-year survival rate 
of graft, increase in the rejection incidence, and decrease in the long-term graft survival and 
the short-term and long-term survival rate of patients. Various medical modalities may 
decrease the incidence of DGF:  
1. To choose young donors and ensure good match of the graft with the recipient.  
2. To reduce warm and cold ischemia time.  
3. To assess the graft quality and utilize optimal renal grafts.  
4. To preserve renal grafts by pulsatile mechanical perfusion.  
5. To administer small doses of calcineurin inhibitors (CNIs), biological 
immunosuppressants and calcium channel blockers. Calcium channel blockers may 
regulate the immune system and reduce acute rejection. In addition, they prevent the 
toxic and adverse effects of CNIs and decrease blood pressure.  
6. To maintain a proper level of mean arterial pressure in the recipient prior to graft 
reperfusion.  
5. Summary 
DGF is an early complication after transplantation caused jointly by immunologic and non-
immunologic factors. Various novel immunosuppressants can effectively control or relieve 
immunologic graft injury, thus improving the short-term and long-term survival rate of 
grafts. However, the mechanism of pre-transplant injury to the renal graft remains largely 
unclear. The risk factors for DGF include the warm ischemia time, cold ischemia time, 
intraoperative and early postoperative hypotension, ATN, nephrotoxicity of CNIs and AR. 
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Further study should be carried out with large sample sizes to investigate the correlation of 
times of transplantation, number of HLA mismatch, early postoperative urinary fistula, 
ureteral obstruction, and preoperative blood transfusion with DGF. Renal graft protection 
has seldom been investigated. Further efforts should be made to prevent non-immunologic 
injury to the renal graft, so as to increase the quality of renal graft and the short-term and 
long-term survival rate of renal grafts.  
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